Joel Sendek - 04 Sep 2025 Form 4 Insider Report for Perspective Therapeutics, Inc. (CATX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CATX
Reported as of: 04 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2025, 16:06:51 UTC
Source filing: View source filing
Reporting owner signature: /s/ Joel Sendek by Chris Nenno, as Attorney-in-Fact

Key filing fact

Joel Sendek filed Form 4 for Perspective Therapeutics, Inc. (CATX) on 05 Sep 2025.

Key facts

This page summarizes Joel Sendek's Form 4 filing for Perspective Therapeutics, Inc. (CATX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Sep 2025, 16:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001720875 Primary reporting owner

Sendek Joel

Relationship: Chief Financial Officer
Address: C/O PERSPECTIVE THERAPEUTICS, INC., 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE
Signature: /s/ Joel Sendek by Chris Nenno, as Attorney-in-Fact
Signature date: 05 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CATX transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +600,000
Change %
Price: $0.000000
Shares after: 600,000
Date: 04 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 600,000
Exercise price: $3.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.